PRME:NSD-Prime Medicine, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.57

Change

-0.11 (-6.55)%

Market Cap

N/A

Volume

1.45M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-0.96 (-0.19%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

-2.03 (-0.34%)

USD 65.38B
ARGX argenx NV ADR

+6.98 (+1.07%)

USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

+14.16 (+5.46%)

USD 30.51B
SMMT Summit Therapeutics PLC

+0.12 (+0.43%)

USD 27.07B
ONC BeiGene, Ltd.

-1.61 (-0.63%)

USD 26.35B
RPRX Royalty Pharma Plc

+0.11 (+0.33%)

USD 18.40B
INSM Insmed Inc

+0.28 (+0.39%)

USD 12.52B
INCY Incyte Corporation

-0.42 (-0.67%)

USD 11.72B
BMRN Biomarin Pharmaceutical Inc

+0.03 (+0.05%)

USD 11.50B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -46.23% 21% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.23% 21% F 13% F
Trailing 12 Months  
Capital Gain -70.93% 28% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.93% 28% F 11% F
Trailing 5 Years  
Capital Gain -92.24% 30% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -92.24% 30% F 9% A-
Average Annual (5 Year Horizon)  
Capital Gain -29.09% 15% F 8% B-
Dividend Return -29.09% 15% F 8% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.55% 89% A- 63% D
Risk Adjusted Return -105.60% 8% B- 4% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector